Table 1.
Summary of sublingual immunotherapy meta-analyses
| Study | Trials/patients | Disease | Results, SMD (95% confidence interval) |
|---|---|---|---|
| Wilson et al15 | 22/979 | AR | Symptoms −0.42 (−0.69 to −0.15; P = 0.002), medication use −0.43 (−0.63 to −0.23; P = 0.00003) |
| Penagos et al16 | 10/484 | AR | Symptoms −0.56 (−1.01 to −0.10; P = 0.02), medication use −0.76 (−1.46 to −0.06; P = 0.03) |
| Olaguíbel et al17 | 7/256 | ARC, asthma | Symptoms AR −0.44 (−1.22 to 0.3; P = 0.27), symptoms AC −1.49 (−3.69 to 0.72; P = 0.19), symptoms asthma −1.42 (−2.51 to −0.34; P = 0.01), medication use −1.01 (−2.06 to 0.04; P = 0.06) |
| Compalati et al18 | 8/382 | AR | Symptoms −0.95 (−1.77 to −0.14; P = 0.02), medication use −1.88 (−3.65 to −0.12; P = 0.04) |
| 9/452 | Asthma | Symptoms −0.95 (−1.74 to −0.15; P = 0.02), medication use −1.48 (−2.70 to −0.26; P = 0.02) | |
| Radulovic et al23 | 49/4589 | AR | Symptoms −0.49 (−0.64 to −0.34; P < 0.00001), medication use −0.32 (−0.43 to −0.21; P < 0.00001) |
| Calderon et al24 | 42/3958 | AC | Symptoms −0.41 (−0.53 to −0.28; P < 0.00001), medication use −0.10 (−0.22 to 0.03; P = 0.13) |
| Penagos et al26 | 9/441 | Asthma | Symptoms −1.14 (−2.1 to −0.18; P = 0.02), medication use −1.63 (−2.83 to −0.44; P = 0.007) |
| Dretzke et al27 | 42 | AR | Symptoms −0.33 (−0.42 to −0.25; P < 0.00001), medication use −0.27 (−0.37 to −0.17; P < 0.00001) |
Abbreviations: SMD, standardized mean difference; AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AC, allergic conjunctivitis.